Breaking News
Ad-Free Version. Upgrade your experience. Save up to 40% More details

Eisai Co Ltd ADR (ESALY)

Create Alert
Create Alert
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile






Delivery Method


Add to/Remove from a Portfolio Add to Portfolio
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
82.72 -2.58    -3.02%
19:00:00 - Delayed Data. Currency in USD ( Disclaimer )
Type:  Equity
Market:  United States
ISIN:  US2825793092 
S/N:  282579309
  • Volume: 15,689
  • Bid/Ask: 0.00 / 0.00
  • Day's Range: 81.90 - 83.15
Eisai Co ADR 82.72 -2.58 -3.02%
IndustryBiotechnology & Drugs


Equity Type


Eisai Co., Ltd. is a Japan-based pharmaceutical company mainly engaged in the research and development, manufacture, sale, import and export of pharmaceuticals. The Company operates in two business segments. The Pharmaceutical segment is engaged in the research, development, manufacture and sale of pharmaceuticals for medical use, generic drugs, general medicines, among others. The segment operates in five regions including Japan, Americas (North America), China, EMEA (Europe, Middle East, Africa, Oceania), Asia and Latin America (South Korea, Taiwan, Hong Kong, India, ASEAN, Latin America). The Others segment is involved in license revenues and pharmaceutical raw materials business. The Company is also engaged in the provision of brands such as the anticancer drugs Lembima and Halaven on the nerve and oncology areas.

Contact Information

Phone +81-3-38173700
Fax 3-38113305

Top Executives

Name Age Since Title
Haruo Naito 72 2014 Chief Executive Officer, Representative Executive Officer, Director
Yutaka Tsuchiya 68 2017 Director
Hideki Hayashi 62 2019 Director
Yasushi Okada 61 2019 Representative Executive Officer, Chief Operating Officer
Kenta Takahashi 60 2019 Senior Managing Executive Officer, General Counsel, President of Subsidiary
Edward Stewart Geary 57 2019 Managing Executive Officer, Global Safety Officer, Chief Director of Global Safety
Gary Hendler 53 2016 Managing Executive Officer, President of EMEA Region, Chief Commercial Officer of Oncology Business
Ivan Cheung 43 2020 Managing Executive Officer, President of Neurology Business Group, Chairman of Subsidiary
Takashi Ohwa 57 2016 Executive Officer, Chief Medicine Creation Officer of Oncology Business Group, Chief Discovery Offic
Terushige Iike 56 2016 Managing Executive Officer, President of Oncology Business Group
Hirokazu Kanai 60 2016 Director
Lynn Kramer 69 2016 Executive Officer, Chief Clinical Officer of Neurology Business Group, Chief Medical Officer of Neur
Ryohei Yanagi 58 2019 Senior Managing Executive Officer, Chief Financial Officer
Sayoko Sasaki 51 2020 Executive Officer, Chief IR Officer
Junichi Asatani 59 2020 Executive Officer
Teiji Kimura 57 2016 Executive Officer, Chief Discovery Officer of Neurology Business Group
Hidenori Yabune 50 2019 Managing Executive Officer, President of Eisai Japan
Yasuhiko Kato 73 2018 Chairman of the Board of Directors, Independent Director
Daiken Tsunoda 53 2016 Independent Director
Hiroyuki Kato 62 2019 Managing Executive Officer, Chief Product Quality Officer, Chief Clinical Quality Officer
Alexander Scott 55 2020 Executive Officer
Masayuki Miyajima 58 2019 Executive Officer, President of Subsidiary
Tatsuyuki Yasuno 52 2020 Managing Executive Officer, President of Americas Region, President of Subsidiary
Yanhui Feng 48 2020 Managing Executive Officer, General Manager of Subsidiaries
Bruce Aronson 68 2017 Independent Director
Yoshiteru Kato 60 2020 Managing Executive Officer, President of Eisai Demand Chain Systems
Mitsuaki Tanaka 58 2020 Executive Officer, Chief Compliance Officer, Chief Information Security Officer
Shohei Kanazawa 55 2020 Executive Officer, President of Asia and Latin America Region
Masatomi Akana 53 2020 Managing Executive Officer, Chief Government Relations Officer
Shuzo Kaihori 73 2018 Independent Director
Ryuichi Murata 72 2018 Independent Director
Hideyo Uchiyama 67 2018 Independent Director
Akiko Nakahama 52 2018 Executive Officer, Manager of Medicine Development Center
Kazumasa Nagayama 40 2019 Executive Officer, Chief Strategy Officer, Director of Corporate Strategy, Director of Corporate Ven
Yosuke Akita 55 2019 Executive Officer, Chief Talent Officer
Kappei Tsukahara 55 2019 Executive Officer, Chief Data Officer, Director of Tsukuba Research Institute
Hiroyuki Murayama 52 2020 Executive Officer, Chief Director of Medical
Keisuke Naito 32 2020 Executive Officer, Chief Digital Officer, President of Dimencia Total Inclusive Ecosystem Unit
Yumiko Miwa 54 2020 Independent Director
Eriko Naito 53 - Executive Officer, President of Consumer hhc Business Unit
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at’s discretion.

ESALY Comments

Write your thoughts about Eisai Co Ltd ADR
Are you sure you want to delete this chart?
Post also to:
Replace the attached chart with a new chart ?
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Are you sure you want to delete this chart?
Replace the attached chart with a new chart ?
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
Sign up with Email